Your browser doesn't support javascript.
loading
Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Redondo, Andres; Oaknin, Ana; Rubio, Maria Jesus; Barretina-Ginesta, Maria-Pilar; de Juan, Ana; Manso, Luis; Romero, Ignacio; Martin-Lorente, Cristina; Poveda, Andres; Gonzalez-Martin, Antonio.
Afiliação
  • Redondo A; Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Universidad Autónoma de Madrid, Paseo de la Castellana, 261, 28046, Madrid, Spain. andres.redondos@uam.es.
  • Oaknin A; Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Rubio MJ; Medical Oncology Department, Hospital Universitario Reina Sofía, Universidad de Córdoba (UCO), Córdoba, Spain.
  • Barretina-Ginesta MP; Medical Oncology Department, Girona Biomedical Research Institute (IdIBGi) and Department of Medical Sciences, Catalan Institute of Oncology (ICO), Medical School University of Girona, Girona, Spain.
  • de Juan A; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Manso L; Medical Oncology Department, Hospital Universitario 12 de Octubre-i+12, Madrid, Spain.
  • Romero I; Medical Oncology Department, Instituto Valenciano Oncologia, Valencia, Spain.
  • Martin-Lorente C; Medical Oncology Department, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Poveda A; Oncogynecologic Department, Initia Oncology, Hospital Quironsalud, Valencia, Spain.
  • Gonzalez-Martin A; Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
J Ovarian Res ; 14(1): 72, 2021 May 26.
Article em En | MEDLINE | ID: mdl-34039386
ABSTRACT

BACKGROUND:

To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors.

METHODS:

The questionnaire was developed by the byline authors. All questions but one were answered using a 9-item Likert-like scale with three types of answers frequency, relevance and agreement. We performed two rounds between December 2018 and July 2019. A consensus was considered reached when at least 75% of the answers were located within three consecutive points of the Likert scale.

RESULTS:

In the first round, 32 oncologists and gynecologists were invited to participate, and 31 (96.9%) completed the online questionnaire. In the second round, 27 (87.1%) completed the online questionnaire. The results for the questions on first-line management of advanced disease, treatment of patients with recurrent disease for whom platinum might be the best option, and treatment of patients with recurrent disease for whom platinum might not be the best option are presented.

CONCLUSIONS:

This survey shows a snapshot of current recommendations by this selected group of physicians. Although the majority of the agreements and recommendations are aligned with the recently published ESMO-ESGO consensus, there are some discrepancies that can be explained by differences in the interpretation of certain clinical trials, reimbursement or accessibility issues.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Guideline Limite: Female / Humans País/Região como assunto: Europa Idioma: En Revista: J Ovarian Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Guideline Limite: Female / Humans País/Região como assunto: Europa Idioma: En Revista: J Ovarian Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha